keyword
MENU ▼
Read by QxMD icon Read
search

Olmetec

keyword
https://www.readbyqxmd.com/read/27180444/comparative-bioavailability-of-a-fixed-dose-combination-tablet-of-olmesartan-medoxomil-hydrochlorothiazide-in-healthy-korean-volunteers
#1
RANDOMIZED CONTROLLED TRIAL
Renhua Zheng, Ho Min Hwang, Bo-Hyung Kim
Combination therapy with diuretics and angiotensin II type 1 (AT1) receptor antagonist is frequently recommended for the control of blood pressure in hypertensive patients. This study was targeted to compare pharmacokinetic profiles of a new generic fixed-dose combination (FDC) tablet of olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg and a reference formulation of Olmetec Plus 20/12.5 mg tablets in healthy volunteers. The study design was a randomized sequence and two-way crossover study in healthy subjects...
March 2016: Acta Poloniae Pharmaceutica
https://www.readbyqxmd.com/read/26067144/-enteropathy-due-to-olmesartan
#2
M Ould Sidi Mohamed, P Colardelle
The olmesartan is a selective antagonist of angiotensin II indicated for the treatment of essential hypertension. We report the case of a gastrointestinal involvement with duodenal villous atrophy and lymphocytic infiltrate duodenal epithelial and colonic secondary to the olmesartan taking with test of positive reintroduction. The patient had chronic diarrhea with weight loss of 10kg occurred 1 month after the passage of 20 to 40mg/day olmesartan took 3 years. A rectosigmoidoscopy highlighted some puncture slightly erythematous areas...
April 2016: Annales de Cardiologie et D'angéiologie
https://www.readbyqxmd.com/read/25567150/-the-effects-of-olmesartan-on-ambulatory-blood-pressures-and-blood-pressure-variability-in-patients-with-mild-to-moderate-essential-hypertension
#3
RANDOMIZED CONTROLLED TRIAL
Jing Li, Tingli Qin, Hong Jiang, Hao Wang, Yuannan Ke
OBJECTIVE: To evaluate the effect of olmesartan medoxomil tablets (olmesartan) in comparison with Olmetec on 24 h ambulatory blood pressure (ABPM) and blood pressure variability (BPV) in patients with mild to moderate hypertension. METHODS: A randomized, double-blind, double-mimic controlled trial was performed.Forty-eight patients with mild to moderate essential hypertension were randomly into treatment group (olmesartan) and control group (Olmetec) for eight weeks...
October 2014: Zhonghua Nei Ke za Zhi [Chinese Journal of Internal Medicine]
https://www.readbyqxmd.com/read/18547134/olmesartan-medoxomil-a-review-of-its-use-in-the-management-of-hypertension
#4
REVIEW
Lesley J Scott, Paul L McCormack
Olmesartan medoxomil (Olmetec, Benicar) is an angiotensin II type 1 (AT(1)) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system, which plays a key role in the pathogenesis of hypertension. Oral olmesartan medoxomil 10-40 mg once daily is recommended for the treatment of adult patients with hypertension. In those with inadequate BP control using monotherapy, fixed-dose olmesartan medoxomil/hydrochlorothiazide (HCTZ) [Olmetec plus, Benicar-HCT] combination therapy may be initiated...
2008: Drugs
https://www.readbyqxmd.com/read/17511387/-medication-of-the-month-olmesartan-medoxomil-hydroclorothiazide-olmetec-plus-or-belsar-plus
#5
REVIEW
P Lancellotti
The therapeutic control of hypertension is still a global challenge and frequently requires combination therapy. Olmesartan medoxomil hydrochlorothiazide (Olmetec plus, Belsar plus) is a fixed-dose combination of olmesartan 20 mg and hydrochlorothiazide 12.5 or 25 mg. Olmesartan is a well known angiotensin II AT1 receptor blocker characterized by a good efficacy, a fast and prolonged duration of action and a placebo-like tolerability. With the combination therapy, no significant change of pharmacokinetics of either component is observed...
March 2007: Revue Médicale de Liège
https://www.readbyqxmd.com/read/15623083/-the-drug-of-the-month-olmesartan-medoxomil
#6
COMPARATIVE STUDY
J M Krzesinski, A J Scheen
Olmesartan medoxomil (Belsar, Olmetec) developed by Sankyo Pharma and proposed by Sankyo Pharma but also Menarini is a new angiotensin II ATI receptor blocker. Its indication is the treatment of hypertension. Olmesartan is indeed an antihypertensive agent with an efficacy dependent on the dose from 10 to 40 mg. It is taken once a day, because of a long duration of action. This prodrug has a dual elimination pathway (biliary and renal). The contraindications are the same as for the other sartans. One of its main advantage, besides its rapidly observed efficacy to lower high blood pressure, is its relatively low cost within this family...
October 2004: Revue Médicale de Liège
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"